Blurbs

Noble Financial Thinks BioSig Technologies’ Stock is Going to Recover

In a report released today, Gregory Aurand from Noble Financial maintained a Buy rating on BioSig Technologies (BSGMResearch Report), with a price target of $4.00. The company’s shares closed last Thursday at $0.64, close to its 52-week low of $0.51.

According to TipRanks.com, Aurand is ranked #7709 out of 7952 analysts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioSig Technologies with a $4.00 average price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $4.11 and a one-year low of $0.51. Currently, BioSig Technologies has an average volume of 318.8K.

Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BSGM in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioSig Technologies, Inc. is a medical technology company developing a proprietary biomedical signal processing platform designed to improve the electrophysiology (EP) marketplace. The company is preparing to commercialize its PURE EP™ System. The technology has been developed to address an unmet need in a large and growing market. Its first product, PURE EP™ System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory. The system is indicated for use under the supervision of licensed healthcare practitioners who are responsible for interpreting the data. This novel cardiac signal acquisition and display system is engineered to assist electrophysiologists in clinical decision-making during electrophysiology procedures in patients with abnormal heart rates and rhythms. Its ultimate goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. The company was founded by Kenneth L. Londoner on February 24, 2009 and is headquartered in Westport. CT.

Read More on BSGM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos